Canadian optical molecular imaging developer ART Advanced Research Technologies (ART) has completed a corporate reorganization as part of an arrangement with its security holders.
ART has realized proceeds of $5.85 million and additional net proceeds of $1.5 million through the sale of some of its common shares, making the company's total nondilutive financing $7.35 million before transaction expenses, with proceeds to be used for general corporate purposes, according to the Saint-Laurent, Quebec-based firm.
By AuntMinnie.com staff writers
November 29, 2006
Related Reading
ART repurchases debentures, November 21, 2006
Road to RSNA, Advanced Research Technologies, November 9, 2006
ART reorganizes for $6.6 million investment, September 22, 2006
Bouchard steps down as ART pres/CEO, July 20, 2006
ART files with Health Canada, June 22, 2006
Copyright © 2006 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
